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Abstract
Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a significant cause of mortality of
COPD patients, and pose a huge burden on healthcare. One of the major causes of AECOPD is airway bacterial (e.g.
nontypeable Haemophilus influenzae [NTHi]) infection. However, the mechanisms underlying bacterial infections during
AECOPD remain poorly understood. As neutrophilic inflammation including increased release of human neutrophil elastase
(HNE) is a salient feature of AECOPD, we hypothesized that HNE impairs airway epithelial defense against NTHi by degrading
airway epithelial host defense proteins such as short palate, lung, and nasal epithelium clone 1 (SPLUNC1).
Methodology/Main Results: Recombinant human SPLUNC1 protein was incubated with HNE to confirm SPLUNC1
degradation by HNE. To determine if HNE-mediated impairment of host defense against NTHi was SPLUNC1-dependent,
SPLUNC1 protein was added to HNE-treated primary normal human airway epithelial cells. The in vivo function of SPLUNC1
in NTHi defense was investigated by infecting SPLUNC1 knockout and wild-type mice intranasally with NTHi. We found that:
(1) HNE directly increased NTHi load in human airway epithelial cells; (2) HNE degraded human SPLUNC1 protein; (3)
Recombinant SPLUNC1 protein reduced NTHi levels in HNE-treated human airway epithelial cells; (4) NTHi levels in lungs of
SPLUNC1 knockout mice were increased compared to wild-type mice; and (5) SPLUNC1 was reduced in lungs of COPD
patients.
Conclusions: Our findings suggest that SPLUNC1 degradation by neutrophil elastase may increase airway susceptibility to
bacterial infections. SPLUNC1 therapy likely attenuates bacterial infections during AECOPD.
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Introduction
COPD is the 3rd leading cause of death in the US [1,2]. One of
the major challenges in COPD healthcare is to prevent and treat
acute exacerbations of COPD (AECOPD). AECOPD is mainly
caused by respiratory bacterial (e.g., nontypeable Haemophilus
influenzae, NTHi) and viral (e.g., rhinovirus) infections [3].
Recurrent respiratory infections in COPD patients suggest
impaired lung defense mechanisms. Although various mechanisms
have been proposed or investigated for respiratory infection-
induced AECOPD, many research questions remain to be
answered. Further defining mechanisms underlying AECOPD is
necessary to discover more effective therapies.
COPD lung including airways is inflamed, especially during
AECOPD. One of the prominent inflammatory cells in COPD
lungs is neutrophils [4,5]. During their activation, neutrophils
release various mediators such as cytokines and proteases, which
contribute to COPD pathogenesis including AECOPD. Among
the proteases released from neutrophils, human neutrophil elastase
(HNE) is particularly important. First, HNE levels are higher in
COPD patients than normal subjects [6,7]. Second, HNE exerts
various deleterious effects on lung immunity and structure such as
degradation of surfactant proteins and induction of emphysema
[8–10].
Because airway epithelial cells represent the first line of lung
responses to invading bacteria, we sought to determine if HNE
impairs airway epithelial host defense functions. In the current
study, we focused on the effects of HNE on the function of a
recently described host defense protein short palate, lung, and
nasal epithelium clone 1 (SPLUNC1). A previous study suggests
that HNE is involved in SPLUNC1 degradation [11]. However,
the role of HNE-mediated SPLUNC1 degradation in host defense
against bacterial infection has not been investigated.
SPLUNC1 is produced by large airway epithelial cells in
humans and mice [12–14]. Human and mouse SPLUNC1
proteins at their precursor (non-secreted) forms have 256 and
278 amino acids (AA), respectively. When secreted, the N-terminal
19 AA signal peptide of SPLUNC1 precursor is cleaved to form
the mature protein. Based on its structural homology to
bactericidal permeability-increasing protein (BPI, a protein mainly
from neutrophil granules) [15], SPLUNC1 has been predicted to
exert an antimicrobial activity [16,17]. Our published data suggest
that SPLUNC1 inhibited the growth ofMycoplasma pneumoniae (Mp)
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[18], a bacterium involved in asthma as well as COPD. Using our
recently generated SPLUNC12/2 mice, we further confirmed the
in vivo host defense function of SPLUNC1 during Mp infection
[19]. Reduced SPLUNC1 protein has been reported in nasal
lavage fluid of ‘‘healthy’’ human smokers [20,21]. Moreover,
SPLUNC1 expression is lower in brushed bronchial epithelial cells
from ‘‘healthy’’ smokers than healthy non-smokers [22].
We hypothesized that HNE impairs human lung defense
functions by decreasing airway epithelial SPLUNC1 levels. Our
current study demonstrates that: (1) HNE directly reduced human
airway epithelial defense against NTHi; (2) HNE degraded human
SPLUNC1 protein; (3) Recombinant SPLUNC1 protein reduced
NTHi levels in HNE-treated human airway epithelial cells; (4)
NTHi levels in lungs of SPLUNC1 knockout mice were increased
compared to wild-type mice; and (5) SPLUNC1 was reduced in
lungs of COPD patients. Together, our findings provide a novel
mechanism underlying bacterial infections in COPD patients, and
a potential therapy to more effectively treat AECOPD.
Methods
Ethics Statement
Experimental animals used in this study were covered by a
protocol approved by Institutional Animal Care and Use
Committee (IACUC) of National Jewish Health, Denver, Color-
ado, USA. All experimental procedures were carried out to
minimize animal discomfort, distress, and pain by following the
American Veterinary Medical Association Guidelines. All human
materials such as bronchoalveolar lavage used in this study were
approved by Institutional Review Board (IRB) of National Jewish
Health, Denver, Colorado, USA. The written informed consent
was waived by National Jewish Health IRB for de-identified organ
donors without lung diseases from whom primary normal human
tracheobronchial epithelial cells were obtained through the
International Institute for the Advancement of Medicine (IIAM)
(http://www.iiam.org).
Generation of Recombinant Human SPLUNC1 Protein
Recombinant human SPLUNC1 protein was generated as we
previously reported [23,24].
Incubation of Recombinant Human SPLUNC1 Protein
with Human Neutrophil Elastase (HNE)
HNE was purchased from the Elastin Product Company
(Pacific, MO), and diluted in 0.05 M sodium acetate solution
with 0.1 M NaCl (pH 5.0). SPLUNC1 protein at 10 mg/ml, a
physiologic dose as we reported [23], was incubated with HNE
(1 mg/ml [or 0.04 U, enzymatic activity] to 50 mg/ml [2.18 U], a
dose range reflecting COPD lungs [25]) or 0.05 M sodium acetate
solution (vehicle, control) in 96-well plates at 37uC for 30 minutes.
At the end of incubation, SPLUNC1 protein was analyzed by
Western blot.
HNE Treatment in Cultured Well-differentiated Primary
Human Airway Epithelial Cells
Primary normal human tracheobronchial epithelial cells were
obtained from tracheas and bronchi of deidentified organ donors
by digesting the tissue with 0.2% protease solution and then
subjected to air-liquid interface (ALI) cultures, as we reported [26].
On day 6 of ALI culture, antibiotic gentamicin was removed from
both apical surface and basolateral side. On day 10 of ALI culture,
cells were treated at the apical surface with HNE (1 to 50 mg/ml)
or vehicle solution. At indicated time points, apical supernatants
were collected to measure SPLUNC1 levels by using an ELISA
[18,23].
NTHi Infection in Cultured Well-differentiated Primary
Human Airway Epithelial Cells
Nontypeable Haemophilus influenzae (NTHi) strain 12 (kindly
provided by Dr. Stephen J. Barenkamp, Saint Louis University
School of Medicine, Saint Louis, MO) was plated on chocolate
agar plates and incubated overnight at 37uC in 5% CO2. A single
colony was used to inoculate 10 ml of brain heart infusion broth
(Remel, Lenexa, KS), and allowed to grow overnight. The
subculture was then washed twice with PBS and the optical
density (O.D.) at a wavelength of 620 nm was determined to
obtain the colony-forming unit (CFU) [27].
To determine if HNE treatment impairs epithelial defense
against NTHi, cells on day 10 of ALI culture were treated at the
apical surface with 50 ml of HNE (10 mg/ml) in the presence or
absence of NTHi at 103 CFU/transwell [28,29]. After 48 hrs of
infection, apical supernatants were collected to measure NTHi
levels. To quantify cell-associated NTHi, epithelial cells were
dissociated by incubation with collagenase I. Briefly, cells on the
transwell membrane were treated at 37uC for 2 hrs with
collagenase I (0.25 mg/ml) supplemented with DNase I (10 mg/
ml), EDTA (2 mM) and DTT (0.5 mg/ml). Thereafter, cells were
scraped and transferred into a 1.5 ml tube for incubation with the
collagenase solution for additional 3 hrs at 37uC on a rocker
(225 rpm) to further dissociate the cells. Thereafter, cells were
spun down to remove the collagenase solution, followed by adding
the trypsin/EDTA solution for incubation at 37uC for 5 min.
After removal of trypsin/EDTA solution, cell pellets were
resuspended in PBS and plated on chocolate agar plates to
quantify NTHi.
To test if SPLUNC1 reduction in HNE-treated cells is
responsible for increased NTHi levels, recombinant human
SPLUNC1 protein (10 mg/ml) or control protein from HEK293
cells was added to the apical surface of epithelial cells after 2 hrs of
HNE treatment and NTHi infection. After 46 hrs of SPLUNC1
treatment or after 48 hrs of NTHi infection, apical supernatants
and cells were harvested for NTHi quantification.
NTHi Infection in SPLUNC1 Knockout Mice
SPLUNC1 knockout (KO) mouse model was used to reveal the
in vivo function of SPLUNC1 against NTHi. SPLUNC1 KO mice
on the C57BL/6 background were generated in our laboratory
and bred under pathogen-free housing conditions as previously
reported [19]. SPLUNC1 KO and wild-type control mice were
intranasally inoculated with NTHi (105 colony forming unit
[CFU]/mouse in 50 ml saline), and sacrificed after 24 hrs of
infection to obtain the lung tissue for NTHi quantification. Briefly,
lung tissues were homogenized and plated on chocolate agar paltes
to count NTHi CFUs. All the experimental protocols were
approved by Institutional Animal Care and Use Committee
(IACUC) at National Jewish Health.
Measurement of SPLUNC1 in COPD Lungs
We obtained bronchoalveolar lavage (BAL) fluid from healthy
non-smokers and smokers, as well as smokers with moderate to
severe COPD patients (Table 1) to measure SPLUNC1 protein by
using a SPLUNC1 ELISA [18,23]. Our research protocol was
approved by the Institutional Review Board (IRB) at National
Jewish Health.
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Statistical Analyses
One-way analysis of variance (ANOVA) was used for multiple
comparisons, and a Turkey’s post hoc test was applied where
appropriate. P,0.05 was considered significant.
Results
HNE Degrades Recombinant SPLUNC1 Protein
To test if HNE directly degrades SPLUNC1, recombinant
human SPLUNC1 protein at a physiological dose (10 mg/ml) was
incubated with HNE at various doses for 30 minutes. Western blot
analysis demonstrated that HNE treatment significantly reduced
intact SPLUNC1 (25-kD), and resulted in the formation of a 22-
kD SPLUNC1 fragment (loss of a 3-kD peptide) (Figure 1A). We
then used liquid chromatography mass spectrometry (LC/MS) on
a quadrupole time-of-flight (QTOF) mass spectrometer to identify
the 3-kD peptide. As shown in Figure 1B, a 25 amino acid peptide
(F21-T45, total mass: about 3-kD) at the N-terminus of SPLUNC1
protein was identified.
HNE Degrades SPLUNC1 Protein in Cultured Well-
differentiated Human Airway Epithelial Cells
Having shown the ability of HNE to degrade recombinant
SPLUNC1 protein in a cell-free environment, we tested if HNE
reduces SPLUNC1 protein secreted from primary normal human
airway epithelial cells that were well differentiated under air-liquid
interface culture. HNE dose-dependently decreased SPLUNC1
after 4 hrs of HNE treatment (Figure 2A). HNE effects on
SPLUNC1 were sustained even after 48 hrs of HNE treatment
(Figure 2B).
Table 1. Characteristics of human subjects.
Subjects N Age Sex (M/F) Smoking (pack-years) FEV1, % predicted FVC, % predicted FEV1/FVC%
HNS 5 33.064.2 3/2 0 86.560.5 84.062.0 84.060.1
HS 9 50.961.1 7/2 34.563.6 99.164.2 94.864.4 83.061.8
COPD 4 63.564.1 2/2 49.6613.9 67.568.4 79.866.0 63.865.3
HNS=Healthy non-smokers; HS=Healthy smokers; COPD=Chronic obstructive pulmonary diseases; FEV1= forced expiratory volume in the 1
st second; FVC= forced
vital capacity.
doi:10.1371/journal.pone.0064689.t001
Figure 1. Degradation of SPLUNC1 protein by human neutrophil elastase (HNE). (A) Western blot of recombinant human SPLUNC1 protein
(10 mg/ml) that was incubated with HNE for 30 minutes. HNE treatment dose-dependently reduces the native SPLUNC1 protein (25 kD). A fragment
of 22-kD SPLUNC1 was seen in HNE-treated samples. (B) Mass spectrometry analysis of NHE-treated recombinant human SPLUNC1 protein revealed a
25 amino acid peptide F21-T45 (FGGLPVPLDQTLPLNVNPALPLSPT).
doi:10.1371/journal.pone.0064689.g001
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HNE Dose-dependently Increases Bacterial Load in Well-
differentiated Human Airway Epithelial Cells
To determine the effects of HNE on bacterial load, apical
surface of cultured well-differentiated normal human airway
epithelial cells was infected with NTHi for 48 hrs in the presence
or absence of HNE. NTHi levels in the apical supernatants
(Figure 3A) and cells (Figure 3B) were markedly increased in a
HNE dose-dependent manner.
Recombinant Human SPLUNC1 Protein Reduces NTHi
Load in HNE-treated Human Airway Epithelial Cells
To determine if HNE-mediated SPLUNC1 reduction is
responsible for impaired airway epithelial defense against NTHi
(e.g., increased bacterial load), recombinant human SPLUNC1
protein (10 mg/ml) was added 2 hrs after HNE treatment and
NTHi infection. After 48 hrs of infection, NTHi levels were
measured in apical supernatants and cells. First, in line with data
shown in Figure 3, HNE increased NTHi load in both apical
supernatants and epithelial cells. Second, recombinant SPLUNC1
protein consistently reduced NTHi (43% reduction, p,0.05) in
apical supernatants (Figure 4A) of epithelial cells obtained from 5
different donors. Although bacterial levels in HNE-treated
epithelial cells were slightly reduced by SPLUNC1, this reduction
was not statistically significant (Figure 4B). Third, we performed a
time course study to observe the rescuing effect of recombinant
SPLUNC1 protein on HNE-mediated SPLUNC1 reduction. As
shown in Figure 5, in HNE-treated cells, recombinant SPLUNC1
protein increased SPLUNC1 levels at the apical surface for the
entire 48 hrs, particularly during the first 2 hrs.
Increased Lung NTHi Load in SPLUNC1 Knockout Mice
We have shown that SPLUNC1 in cultured human airway
epithelial cells is critical to NTHi defense, but the in vivo function
of SPLUNC1 during NTHi infection is unclear. We utilized our
SPLUNC1 knockout (SPLUNC12/2) mouse model to delineate
the in vivo function of SPLUNC1. After 24 hrs of an intranasal
inoculation of NTHi, bacterial load in SPLUNC12/2 mice was
about 30-fold higher than that in wild-type mice (Figure 6).
Reduced SPLUNC1 in Human COPD Lungs
We measured SPLUNC1 protein levels in BAL fluid of healthy
non-smokers, healthy smokers and stable moderate to severe
COPD patients. As shown in Figure 7, SPLUNC1 protein was
Figure 2. Human neutrophil elastase (HNE) decreases SPLUNC1 protein in cultured human airway epithelial cells. Primary normal
human tracheobronchial epithelial cells (N= 3) were differentiated into the mucociliary phenotype under air-liquid interface culture for 10 days. After
4 (A) and 48 (B) hrs of HNE treatment, SPLUNC1 protein in apical supernatants was measured by an ELISA. Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0064689.g002
Figure 3. Human neutrophil elastase (HNE) dose-dependently increases the load of nontypeable Haemophilus influenzae (NTHi) in
cultured human airway epithelial cells. Primary normal human tracheobronchial epithelial cells (N = 3) were differentiated into the mucociliary
phenotype under air-liquid interface culture for 10 days, and then infected with NTHi for 48 hrs. (A) – NTHi in apical supernatants; (B) – NTHi
associated with epithelial cells. Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0064689.g003
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significantly reduced in smokers with or without COPD as
compared to healthy non-smokers.
Discussion
The current study demonstrates that human neutrophil elastase
(HNE)-mediated SPLUNC1 degradation impairs airway epithelial
defense against bacterial infection. We found that HNE markedly
reduces SPLUNC1 in well-differentiated human airway epithelial
cells and subsequently increases bacterial load, which can be
attenuated by recombinant human SPLUNC1 protein. Moreover,
we found decreased SPLUNC1 in human COPD lungs, and
increased lung bacterial load in SPLUNC1 knockout mice.
Together, our data suggest that increased HNE, a feature of
excessive inflammation during acute exacerbations of COPD and
other chronic lung diseases, may contribute to bacterial infections
in part through degrading host defense protein SPLUNC1.
Acute exacerbations of COPD (AECOPD) pose the highest risk
(i.e., mortality) to patients and the greatest costs for COPD-related
healthcare. Respiratory bacterial and viral infections are the major
cause of AECOPD, which commonly recruit neutrophils into the
airway lumen and activate them. During neutrophil activation,
they release various mediators including HNE. Although the NE
knockout mouse model suggests a beneficial role of intracellular
NE in host defense against bacterial (e.g., Pseudomonas aeruginosa)
infection [30], the impact of released HNE on lung (airway)
bacterial infections remains poorly understood. We have found
increased bacterial (e.g., NTHi) load in HNE-treated well-
differentiated primary human airway epithelial cells. Our data
suggest a new mechanism underlying frequent bacterial infection
during AECOPD that is characterized by excessive lung
Figure 4. Recombinant human SPLUNC1 protein significantly reduces the load of nontypeable Haemophilus influenzae (NTHi) in
apical supernatants of human neutrophil elastase (HNE)-treated human airway epithelial cells. Primary normal human tracheobronchial
epithelial cells (N = 5) were differentiated into the mucociliary phenotype under air-liquid interface culture for 10 days, and then infected with NTHi
(103 CFU/transwell) in the presence or absence of HNE (10 mg/ml). After 2 hrs of NTHi and HNE treatment, recombinant human SPLUNC1 protein
(10 mg/ml) was added to the apical surface of epithelial cells. After 46 hrs of SPLUNC1 treatment or after 48 hrs of NTHi infection, apical supernatants
and cells were harvested for NTHi quantification. (A) – NTHi in apical supernatants; (B) – NTHi associated with epithelial cells. Each connected color
line represents the data collected from cells of an individual donor. The horizontal dotted red lines indicate medians of NTHi fold changes (HNE
treatment versus vehicle solution control).
doi:10.1371/journal.pone.0064689.g004
Figure 5. Time course study of the rescuing effects of
recombinant human SPLUNC1 protein on SPLUNC1 protein
levels in human neutrophil elastase (HNE)-treated human
airway epithelial cells. Primary normal human tracheobronchial
epithelial cells (N = 3) were differentiated into the mucociliary
phenotype under air-liquid interface culture for 10 days, and then
treated with HNE (10 mg/ml) in the presence or absence of recombinant
human SPLUNC1 protein (10 mg/ml). At indicated time points, SPLUNC1
protein in the apical supernatants was measured by using an ELISA.
Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0064689.g005
Figure 6. SPLUNC1 knockout (SPLUNC12/2) mice increase the
load of nontypeable Haemophilus influenzae (NTHi) in the lung.
SPLUNC12/2 and wild-type mice (n = 7 or 8 mice/group) were
intranasally inoculated with NTHi (105 CFUs/mouse). After 24 hrs of
infection, left lungs were homogenized to quantify NTHi load by
culture. The horizontal lines represent means of CFUs.
doi:10.1371/journal.pone.0064689.g006
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inflammation especially neutrophils.
How HNE impairs airway epithelial defense against NTHi is
unclear. Our current study focuses on the effects of HNE on
SPLUNC1 as recent studies suggest that SPLUNC1 exerts both
in vitro and in vivo host defense functions [18,19,31]. First, we
demonstrated that in a cell-free environment, HNE dose-
dependently reduced SPLUNC1 levels. By Western blot analysis,
we identified a 22-kD SPLUNC1 fragment resulting from HNE
treatment, suggesting a loss of 3-kD peptide from the 25 kD native
SPLUNC1 protein. By using mass spectrometry, we identified a 25
amino acid peptide (mass: ,3 kD), suggesting a cutting site by
HNE. Whether other sites of SPLUNC1 protein can be cut by
HNE remains to be explored. Second, we confirmed that HNE
also reduced SPLUNC1 levels in cultured well-differentiated
primary normal human airway epithelial cells. Interestingly, the
differences of SPLUNC1 levels between HNE-treated and control
(no HNE) cells were smaller at 48 hr than at 4 hr, which may be
explained by several factors, including continuous secretion of
SPLUNC1 protein from epithelial cells, the loss of HNE activity
over time and secretion of protease inhibitors from epithelial cells.
Collectively, our data indicate that HNE can degrade SPLUNC1
secreted from airway epithelial cells under a neutrophilic
inflammatory setting.
One of the major research questions is whether HNE-mediated
SPLUNC1 reduction/degradation in airway epithelial cells is
responsible for increased bacterial load following HNE treatment.
To address this, we tested the therapeutic effects of recombinant
human SPLUNC1 protein on NTHi load in HNE-treated cells.
We confirmed that SPLUNC1 protein was able to restore
epithelial defense functions by decreasing NTHi levels. Moreover,
we demonstrated a critical in vivo role of SPLUNC1 in lung
defense against NTHi by using the SPLUNC1 knockout mouse
model. Together, our data suggest that SPLUNC1 protein may
serve as a novel approach to treat bacterial infections in various
lung diseases characterized by excessive neutrophilic inflamma-
tion. Although recombinant SPLUNC1 protein reduced bacterial
load in HNE-treated airway epithelial cell, it did not reduce the
bacteria to the normal level. This suggests that HNE may use
other mechanisms to increase bacterial load. Indeed, a previous
study demonstrated that HNE increased epithelial permeability
[32]. Therefore, it is possible that HNE could increase bacterial
binding in part through disrupting epithelial barrier function in
our cell culture model. The contribution of HNE-mediated
SPLUNC1 reduction versus epithelial barrier disruption to
increased bacterial load will be investigated in our future studies.
Although the current study was focused on in vitro studies, we
examined SPLUNC1 levels in COPD lungs. We found reduced
SPLUNC1 levels in COPD patients as compared to healthy
controls, especially healthy non-smokers. Interestingly, SPLUNC1
levels in healthy smokers were less than those in healthy non-
smokers. We realize that SPLUNC1 reduction in vivo may be
caused by multiple factors. We measured HNE levels in BAL fluid
of COPD patients who were stable during the BAL procedure and
control subjects, and did not find a significant difference of HNE.
This may be explained by the fact that our patients undergoing
bronchoscopy and BAL fluid procedure were stable (no acute
exacerbations). Therefore, SPLUNC1 reduction in stable COPD
patients may be caused by other factors such as cigarette smoke
exposure. In a pilot study, we exposed well-differentiated human
airway epithelial cells to whole cigarette smoke or air (control) for
10 minutes as we described before [33]. After 24 hrs of cigarette
smoke exposure, SPLUNC1 levels in the apical surface were
reduced by 40%. Future studies should correlate SPLUNC1 levels
with HNE and bacterial load in COPD patients before, during
and after acute exacerbations. This could be done by obtaining
sputum samples, as sputum collection is safer than the bronchos-
copy procedure for patients during AECOPD.
Our current study has several limitations. First, we only used
normal human airway epithelial cells to study the impact of HNE
on SPLUNC1 degradation and bacterial infection. We will
consider COPD airway epithelial cells in our future studies to
determine if COPD cells may differ from normal cells in their
responses to HNE and NTHi infection. Second, since NTHi was
the only strain of bacteria examined in the current study, our
results should be verified in other strains of bacteria involved in
COPD, including Pseudomonas aeruginosa. Third, HNE may degrade
other antimicrobial substances (e.g., surfactant protein A, [8]) that
promote host defense against bacteria. The relative contribution of
HNE-mediated reduction of SPLUNC1 versus other antimicrobial
mediators should be dissected in future studies. Lastly, we realize
the variability of bacterial load data in human airway epithelial
cells from different donors. This may be caused by the variation in
susceptibility of different donor cells to bacterial infection. More
experiments from additional donors may be needed to address the
underlying mechanisms of NTHi load variation. Furthermore,
in vivo (e.g., mouse) studies are warranted to determine the
physiological significance of a less than one log bacterial load
change in cultured well-differentiated human primary airway
epithelial cells treated with recombinant SPLUNC1 protein and/
or HNE.
In summary, our current study provides a new mechanism to
explain increased susceptibility of COPD patients to bacterial
infections, in particular during acute exacerbations that are
featured with excessive neutrophilic inflammation and release of
neutrophil elastase. As SPLUNC1 is an endogenous protein and
unlikely has the side effects (e.g., drug resistance) of antibiotics, it
has the potential to treat bacterial infections associated with
AECOPD and perhaps other lung diseases such as asthma and
cystic fibrosis.
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